MetaCap

Sunshine Biopharma Inc. (SBFM)

NASDAQ: SBFMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.23-0.12 (-5.11%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SBFM stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$620.60
52-week range
2.23 – 464.00
Day range
2.23 – 2.35
Volume / Avg
22.93K / 301.48K
Beta
—

52-week range

$2.23$464.00

SBFM stock today

Sunshine Biopharma (SBFM) closed at $2.23 on Nov 20, down 5.11% (-$0.12), versus the S&P 500's 3.70% decline. Trading was light, with 22.93K shares changing hands, about 8% of the average daily volume. At this level, SBFM sits near the bottom of its 52-week range of $2.23 to $464.00: 99.5% below the high and 0.0% above the low.

Sunshine Biopharma has posted a net loss over the last twelve months (EPS of -$620.60), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Sunshine Biopharma

Company profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Steve N. Slilaty Ph.D.
Headquarters
Fort Lauderdale, FL
Employees
50

Financial highlights

Full financials

In fiscal 2025, Sunshine Biopharma generated $36.3 million in revenue, up 4.1% from fiscal 2024, its 7th consecutive year of revenue growth. Sunshine Biopharma reported a net loss of $6.0 million, compared with a loss of $5.1 million a year earlier. Gross margin was 33.8% (up from 30.6%) and operating margin -17.2%.

Sunshine Biopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$36.31M$34.87M$24.09M$4.35M$228.43K
Growth+4.11%+44.75%+454.42%+1802.41%+219.88%
Net income$-5.98M$-5.13M$-4.51M$-26.74M$-12.44M
EPS (diluted)—$-7.32$-351.36$-1.76$-4.76

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$56.00+2411.21%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-5.20 vs —

SBFM news

All SBFM news

Sunshine Biopharma peers

Health Care sector
SBFM peer companies
CompanyPrice% ChgMarket capCompare
PPBTPurple Biotech Ltd. ADR1.53-4.09%$1.86Mvs SBFM
PPCBPropanc Biopharma Inc.1.78+3.19%$1.87Mvs SBFM
XRTXXORTX Therapeutics Inc.0.839-5.73%$1.88Mvs SBFM
EOCNEocene Ltd.1.78+1.73%$1.90Mvs SBFM
KALAKALA BIO Inc.2.71-10.28%$1.74Mvs SBFM
GNPXGenprex Inc.1.45-13.17%$1.94Mvs SBFM
DCOYDecoy Therapeutics Inc.0.8294-4.68%$1.98Mvs SBFM
REVBRevelation Biosciences Inc.3.50-5.15%$1.99Mvs SBFM

Indexes, lists and sector

Sunshine Biopharma stock FAQ

What is Sunshine Biopharma's stock price today?

SBFM last traded at $2.23 as of Nov 20, 4:00 PM EST, down 5.11% on the day. Prices are delayed at least 15 minutes.

Does Sunshine Biopharma pay a dividend?

No. Sunshine Biopharma does not currently pay a regular cash dividend.

Who is Sunshine Biopharma's CEO?

Dr. Steve N. Slilaty Ph.D. is the chief executive officer of Sunshine Biopharma Inc., which has about 50 employees.

Has SBFM ever split its stock?

Yes. The most recent SBFM stock split was a 1-for-20 split on Oct 26, 2026.

What is the SBFM 52-week high?

The 52-week high for SBFM is $464.00 and the 52-week low is $2.23. The stock is currently 99.5% below its high.

Compare SBFM